ArticleJournal of the American Heart Association2026
Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcomitant use of nirmatrelvir/ritonavir with direct oral anticoagulants (DOACs) for COVID-19 is challenging due to potential drug-drug interactions. This study assessed the safety and effectiveness of nirmatrelvir/ritonavir compared with RNA-dependent RNA polymerase inhibitors in patients with COVID-19 and atrial fibrillation treated with a DOAC.
methodsWe conducted a territory-wide retrospective study of patients with COVID-19 hospitalized in Hong Kong between January and November 2022 for antiviral therapy who had atrial fibrillation managed with a DOAC. Clinical outcomes including 30-day all-cause death, ischemic stroke, myocardial infarction, and bleeding events were evaluated.
resultsOverall, 1297 (91%) patients were prescribed an RNA-dependent RNA polymerase inhibitor, and 127 (9%), nirmatrelvir/ritonavir. Among patients treated with nirmatrelvir/ritonavir, 77 (60.6%) continued DOAC treatment, 30 (23.6%) switched to low-molecular-weight heparin, and 20 (15.7%) withheld anticoagulation therapy. After propensity score matching (n=1270), 1143 and 127 patients were in the RNA-dependent RNA polymerase inhibitor and nirmatrelvir/ritonavir groups, respectively. On univariate analysis, the 30-day all-cause death was lower in the nirmatrelvir/ritonavir group (5.51% versus 12.1%;
conclusionsIn a territory-wide cohort of hospitalized patients with COVID-19 and atrial fibrillation on a DOAC, nirmatrelvir/ritonavir therapy was associated with lower unadjusted 30-day all-cause death compared with RNA-dependent RNA polymerase inhibitors; however, this difference was not significant after adjusting for age and COVID-19 severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.